These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 25356419)
1. Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity. Lehmann-Horn K; Kinzel S; Feldmann L; Radelfahr F; Hemmer B; Traffehn S; Bernard CC; Stadelmann C; Brück W; Weber MS Ann Clin Transl Neurol; 2014 Jul; 1(7):490-6. PubMed ID: 25356419 [TBL] [Abstract][Full Text] [Related]
2. Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity. Tesfagiorgis Y; Kemal EA; Craig HC; Parham KA; Kerfoot SM J Neuroimmunol; 2024 Feb; 387():578267. PubMed ID: 38155065 [TBL] [Abstract][Full Text] [Related]
3. Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges. Lehmann-Horn K; Kronsbein HC; Weber MS Ther Adv Neurol Disord; 2013 May; 6(3):161-73. PubMed ID: 23634189 [TBL] [Abstract][Full Text] [Related]
4. The Role of Latently Infected B Cells in CNS Autoimmunity. Márquez AC; Horwitz MS Front Immunol; 2015; 6():544. PubMed ID: 26579121 [TBL] [Abstract][Full Text] [Related]
5. Treatment of multiple sclerosis with anti-CD20 antibodies. Barun B; Bar-Or A Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250 [TBL] [Abstract][Full Text] [Related]
6. Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein. Columba-Cabezas S; Griguoli M; Rosicarelli B; Magliozzi R; Ria F; Serafini B; Aloisi F J Neuroimmunol; 2006 Oct; 179(1-2):76-86. PubMed ID: 16870269 [TBL] [Abstract][Full Text] [Related]
7. The Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple Sclerosis. Ignatius Arokia Doss PM; Roy AP; Wang A; Anderson AC; Rangachari M Front Immunol; 2015; 6():541. PubMed ID: 26557120 [TBL] [Abstract][Full Text] [Related]
8. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948 [TBL] [Abstract][Full Text] [Related]
9. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Hammer LA; Waldner H; Zagon IS; McLaughlin PJ Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376 [TBL] [Abstract][Full Text] [Related]
10. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Komori M; Lin YC; Cortese I; Blake A; Ohayon J; Cherup J; Maric D; Kosa P; Wu T; Bielekova B Ann Clin Transl Neurol; 2016 Mar; 3(3):166-79. PubMed ID: 27042677 [TBL] [Abstract][Full Text] [Related]
11. Late B cell depletion with a human anti-human CD20 IgG1κ monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets. Kap YS; van Driel N; Blezer E; Parren PW; Bleeker WK; Laman JD; Craigen JL; 't Hart BA J Immunol; 2010 Oct; 185(7):3990-4003. PubMed ID: 20739677 [TBL] [Abstract][Full Text] [Related]
12. The role of antibodies in multiple sclerosis. Weber MS; Hemmer B; Cepok S Biochim Biophys Acta; 2011 Feb; 1812(2):239-45. PubMed ID: 20600871 [TBL] [Abstract][Full Text] [Related]
13. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Breuer J; Schwab N; Schneider-Hohendorf T; Marziniak M; Mohan H; Bhatia U; Gross CC; Clausen BE; Weishaupt C; Luger TA; Meuth SG; Loser K; Wiendl H Ann Neurol; 2014 May; 75(5):739-58. PubMed ID: 24771567 [TBL] [Abstract][Full Text] [Related]
15. Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Constantinescu CS; Lavi E Curr Eye Res; 2000 Jan; 20(1):71-6. PubMed ID: 10611718 [TBL] [Abstract][Full Text] [Related]
16. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis. Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035 [TBL] [Abstract][Full Text] [Related]
17. B cell-directed therapies in multiple sclerosis. Gasperi C; Stüve O; Hemmer B Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316 [TBL] [Abstract][Full Text] [Related]
18. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. Magliozzi R; Columba-Cabezas S; Serafini B; Aloisi F J Neuroimmunol; 2004 Mar; 148(1-2):11-23. PubMed ID: 14975582 [TBL] [Abstract][Full Text] [Related]
19. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Bittner S; Ruck T; Wiendl H; Grauer OM; Meuth SG Ther Adv Neurol Disord; 2017 Jan; 10(1):51-66. PubMed ID: 28450895 [TBL] [Abstract][Full Text] [Related]
20. [Meningeal tertiary lymphoid organs: Major actors in intrathecal autoimmunity]. Bonnan M Rev Neurol (Paris); 2015 Jan; 171(1):65-74. PubMed ID: 25555848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]